Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.

Replacement of the flexible connecting chains between the piperidine moiety and an aromatic group in previous CCR5 antagonists with heterocycles, such as pyrazole and isoxazole, provided potent CCR5 antagonists with excellent anti-HIV-1 activity in vitro. SAR studies revealed optimal placement of an unsubstituted nitrogen atom in the heterocycle to be meta to the bond connected to the 4-position of piperidine. Truncation of a benzyl group to a phenyl group afforded compounds with dramatically improved oral bioavailability, albeit with reduced activity.

[1]  J. Haines,et al.  CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis , 2000, Immunogenetics.

[2]  M. Kavanaugh,et al.  A Critical Site in the Core of the CCR5 Chemokine Receptor Required for Binding and Infectivity of Human Immunodeficiency Virus Type 1* , 1999, The Journal of Biological Chemistry.

[3]  P D Leeson,et al.  4-Heterocyclylpiperidines as selective high-affinity ligands at the human dopamine D4 receptor. , 1997, Journal of medicinal chemistry.

[4]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Hazuda,et al.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains. , 2003, Bioorganic & medicinal chemistry letters.

[6]  M. Maccoss,et al.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. , 2001, Bioorganic & medicinal chemistry letters.

[7]  Blair,et al.  HIV-1 entry - an expanding portal for drug discovery. , 2000, Drug discovery today.

[8]  B. Neustadt,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. , 2001, Journal of medicinal chemistry.

[9]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[10]  P. Gray,et al.  Co‐receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands , 2000, Immunological reviews.

[11]  Michael S. Saag,et al.  A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .

[12]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[13]  D. Hazuda,et al.  Combinatorial synthesis of CCR5 antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[14]  M. Shu,et al.  Versatile and efficient solid-phase syntheses of pyrazoles and isoxazoles. , 2000, Organic letters.

[15]  M. Springer,et al.  The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention. , 2000, Current opinion in chemical biology.

[16]  Karen Holmes,et al.  1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains. , 2003, Bioorganic & medicinal chemistry letters.

[17]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[18]  C. Supuran,et al.  Small molecule antagonists of chemokine receptors as emerging anti-HIV agents , 2001 .

[19]  D. Hazuda,et al.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV. , 2002, Bioorganic & medicinal chemistry letters.